Creative Biolabs offers a variety of bispecific antibodies (BsAbs) development services. With years of experience in BsAbs development and manufacture, our scientists are confident in providing high-quality DutaMab in a timely and cost-effective manner.
Therapeutic monoclonal antibodies have emerged as excellent choice to treat cancer, inﬂammatory diseases, and autoimmune disorders. A number of clinical and commercial successes with antibody therapeutics accelerate the development of next generation antibody drugs, including BsAbs. BsAbs that target more than one antigen or epitope on a target cell or recruit effector cells (natural killer cell, T cell, or macrophage cell) toward target cells have display vast potential to maximize the benefits of antibody therapy. Until now, a variety of new concepts to form BsAbs have evolved successfully into many formats from full bispecific immunoglobulin gammas to antibody fragments. Many BsAbs are created to retarget T cells to kill tumor cells, however most others are designed to interact with two different disease mediators, for example, surface receptors, soluble ligands and other proteins.
During BsAbs development, overcoming the mispairing of heavy chain and light chain is a great challenge. A variety of strategies have been developed to solve this problem, for example, using a single kind of heavy and light chain and engineering the variable domains to recognize two unrelated antigens through two different binding sites on the antibody (paratopes). Creative Biolabs offers a novel approach to generate BsAbs with the reduced chain mispairing, known as DutaMab. This strategy uses the diversity of only three CDRs for each antigen thus producing two independent paratopes. In this approach, DutaMab allows the progress of BsAbs on a single arm of the antibodies which are characterized by a high affinity and simultaneous binding against both targets, with good stability and excellent manufacturing properties. The most attractive feature of DutaMabs is that it has a single kind of heavy and light chain and is amenable to standard production processes developed for monospecific antibodies. In addition, it enables to be formatted as a bispecific tetravalent IgG of any isotype.
Figure 1. schematic diagram of DutaMab generation process.
Creative Biolabs has established an excellent DutaMab technology platform. We are proud to provide customized DutaMab generation services for custom. Following items are several excellent properties of our DutaMab:
With our well-established DutaMab technology platform, the experienced scientists here at Creative Biolabs are dedicated to helping you develop therapeutic BsAbs. We also provide other various services regarding BsAbs development. Please feel free to contact us for more information and a detailed quote.
1. Spiess, C.; et al. Alternative molecular formats and therapeutic applications for bispecific antibodies.” Molecular immunology. 2015, 67(2): 95-106.
2. Kontermann, R. E.; Brinkmann, U. Bispecific antibodies. Drug discovery today. 2015, 20(7): 838-847.